Market Place
Sourcing Support
Cash-strapped Cyclacel cuts costs while searching for salvation
06 Dec 2024 //
FIERCE BIOTECH
Cyclacel Pharmaceuticals Closes $2.1M Warrant Exercise
14 Nov 2024 //
GLOBENEWSWIRE
Cyclacel Pharma Announces $2.1M in Warrant Proceeds
13 Nov 2024 //
GLOBENEWSWIRE
Cyclacel Pharma Reports Q3 Financial Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Receives Nasdaq Compliance Extension
24 Oct 2024 //
GLOBENEWSWIRE
Cyclacel Reports New Data from Phase 2 Study of Fadraciclib
23 Oct 2024 //
GLOBENEWSWIRE
Cyclacel To Present Fadraciclib Data At EORTC-NCI-AACR Symposium
09 Oct 2024 //
GLOBENEWSWIRE
Cyclacel Completes Enrollment In Phase 2 Study Cohort
25 Sep 2024 //
GLOBENEWSWIRE
Cyclacel To Participate In H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Appeals Nasdaq Staff Delisting Letter
03 Sep 2024 //
GLOBENEWSWIRE
Cyclacel Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
Cyclacel Announces Notice Of Intention To Grant Patent
26 Jun 2024 //
GLOBENEWSWIRE
Cyclacel: Fadraciclib Efficacy In Colorectal Cancer Models At ASCO 2024
04 Jun 2024 //
GLOBENEWSWIRE
Cyclacel`s Fadraciclib Precision Cancer Med Potential At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Cyclacel Reports Q1 2024 Financial Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
08 May 2024 //
GLOBENEWSWIRE
Cyclacel Closes $8M Private Placement At-The-Market
02 May 2024 //
GLOBENEWSWIRE
Cyclacel $8M Private Placement At-The-Market on Nasdaq
30 Apr 2024 //
GLOBENEWSWIRE
Cyclacel to Present New Clinical Data at ASCO Meeting Highlighting Fadraciclib
01 Apr 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Reports4Q FYR 2023 & Provides Business Update
19 Mar 2024 //
GLOBENEWSWIRE
Cyclacel Pharma Announces the Appointment of Brian Schwartz, M.D. as CMO
30 Jan 2024 //
GLOBENEWSWIRE
Cyclacel Pharma Announces Registered Direct and Private Placement Offering
22 Dec 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data
18 Dec 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Announces Reverse Stock Split
12 Dec 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Cyclacel Reports First Quarter Financial Results and Provides Business Update
11 May 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
04 May 2023 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
07 Mar 2023 //
GLOBENEWSWIRE
Cyclacel Reports Fourth Quarter And Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Cyclacel to Release Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Cyclacel Pharma to Participate in the 2023 BIO CEO & Investor Conference
30 Jan 2023 //
GLOBENEWSWIRE
Cyclacel to Participate in Corp Access Event During the J.P. Morgan Conference
15 Dec 2022 //
GLOBENEWSWIRE
Cyclacel pulls the plug on Daiichi-partnered chemo — after a failed PIII in AML
11 Nov 2022 //
ENDPTS
Cyclacel Pharmaceuticals Reports 3Q 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
Cyclacel Reports Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib
26 Oct 2022 //
GLOBENEWSWIRE
Cyclacel Hosting Research & Development Day
24 Oct 2022 //
GLOBENEWSWIRE
Cyclacel To Present Preliminary Data From The P1/2 Trial Of Oral Fadraciclib
13 Oct 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022
21 Sep 2022 //
GLOBENEWSWIRE
Cyclacel Reports Q2 Financial Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Cyclacel Pharma Achieves Key Business Objectives in First Half of 2022
30 Jun 2022 //
GLOBENEWSWIRE
Cyclacel Pharma Elects Kenneth M. Ferguson to Its Board of Directors
22 Jun 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140
19 Apr 2022 //
GLOBENEWSWIRE
Cyclacel Pharma to Publish Confirming Fadraciclib Suppresses MCL1 and CLL
12 Apr 2022 //
GLOBENEWSWIRE
Cyclacel Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Cyclacel Pharma to Present at 32nd Annual Oppenheimer Healthcare Conference
09 Mar 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
07 Feb 2022 //
GLOBENEWSWIRE
Cyclacel Pharma Reviews 2021 Achievements & Key Business Objectives for 2022
06 Jan 2022 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 VC
23 Dec 2021 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 VC
23 Dec 2021 //
GLOBENEWSWIRE
Cyclacel Begins Dosing in Phase 1/2 Study of Fadraciclib in Leukemias or MDS
05 Nov 2021 //
GLOBENEWSWIRE
Cyclacel Announces Dosing of First Patient in Ph 1/2 Study of Oral Fadraciclib
13 Jul 2021 //
GLOBENEWSWIRE
Cyclacel Pharma to Present at Ladenburg Thalmann’s Virtual Healthcare Conference
07 Jul 2021 //
GLOBENEWSWIRE
Cyclacel Announces Appointment of Mark Kirschbaum, M.D., as CMO
23 Oct 2020 //
GLOBENEWSWIRE
Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation
21 Sep 2020 //
GLOBENEWSWIRE
